Article Text

Download PDFPDF
High prevalence of quinolone resistance in Neisseria gonorrhoeae in coastal Kenya
  1. Sarah Duncan1,
  2. Alexander N Thiong'o2,
  3. Michael Macharia2,
  4. Lorraine Wamuyu2,
  5. Salim Mwarumba2,
  6. Benedict Mvera2,
  7. Adrian D Smith1,
  8. Susan Morpeth2,3,
  9. Susan M Graham2,4,
  10. Eduard J Sanders2,3
  1. 1Department of Public Health, University of Oxford, Headington, UK
  2. 2Centre for Geographic Medicine Research-Coast, Kenya Medical Research Institute (KEMRI)-Kilifi, Kilifi, Kenya
  3. 3Nuffield Department of Clinical Medicine, Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Headington, UK
  4. 4Department of Medicine, University of Washington, Seattle, Washington, USA
  1. Correspondence to Dr Eduard J Sanders, Kenya Medical Research Institute, Centre for Geographic Medicine Research-Coast, PO Box 230, Kilifi, Kenya; esanders{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Untreated or inadequately treated gonorrhoea is associated with significant morbidity and may act as a co-factor in HIV transmission. The WHO currently recommends treatment of gonorrhoea with quinolone, oral cefixime, intramuscular ceftriaxone or spectinomycin. In Kenya, syndromic treatment of male dysuria or discharge includes presumptive treatment for gonorrhoea with quinolone and …

View Full Text


  • Funding International AIDS Vaccine Initiative.

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the National Ethical Review Committee of the Kenya Medical Research Institute.

  • Provenance and peer review Not commissioned; not externally peer reviewed.